Diarrhea Clinical Trial
Official title:
A Randomized, Double-Blinded, Placebo-controlled, Dose-Escalation, Age-Descending Study to Assess the Safety and Tolerability of Live Attenuated, Oral Shigella WRSS1 (Walter Reed S. Sonnei) Vaccine in Bangladeshi Adults and Children
This is a research study about an experimental (investigational) oral Shigella sonnei - Walter Reed S. sonnei (WRSS1). WRSS1 is a live vaccine that is being made to prevent disease from Shigella, which causes bloody, watery diarrhea. Infants and children living in developing countries experience the greatest consequences of this disease. The purpose of this study is to find a dose of the vaccine that is safe, tolerable, and develops an immune response. About 39 healthy adults, ages 18-39, and 48 healthy children, ages 5-9, will participate in this study. Once the vaccine is proven safe and tolerable in adults, then it will be tested in the children. This study will require volunteers to stay in the research facility for several nights for the first dose; they will not be required to stay overnight for the second and third doses. Participants will be assigned to receive 1 of 3 vaccine dose levels by mouth. Study procedures include: stool samples, blood samples and documenting side effects. Participants will be involved in study related procedures for about 8 months.
This is a single site, double-blind, randomized, placebo-controlled, dose-escalation,
age-descending study that will start testing the vaccine in healthy adults and move
subsequently into school-age children. The study is designed as 2 parts, each part comprising
3 cohorts. The cohort receiving the lowest dose in Parts A and B will receive only one
administration of vaccine or placebo; the subsequent two higher dose cohorts in Parts A and B
will receive three administrations of vaccine or placebo. In each cohort, the first dose and
immediate safety evaluation will be conducted at the International Centre for Diarrhoeal
Disease Research (icddr,b) Inpatient Unit, where the participants will be admitted for
observation for 72 hours. Follow-up visits for participants in A1 and B1 will take place on
an outpatient basis at the Mirpur, Bangladesh (Mirpur) Field Office. Second and third
vaccinations within A2, A3, B2, and B3 cohorts and all follow-up visits will take place on an
outpatient basis at the Mirpur Field Office. Before enrolling participants in subsequent
cohorts to receive a higher vaccine dose, or to move to the lower age group, the safety data
from the previous cohort(s) (through Study Day 7) will be evaluated and reviewed by the
Internal Protocol Safety Team (IPST) comprised of the study physician, the Medical Monitor
from GVK Biosciences (GVK), the principal investigator, and the Medical Monitor from PATH
Vaccine Solutions (PVS). Upon completion of the last adult cohort, the Data Safety Monitoring
Board (DSMB -an advisory body to the Ethical Review Committee) will convene to review the
cumulative safety data and IPST recommendation, and determine whether to proceed to Part B
(children). Adverse events (AE)s will be graded according to standardized criteria. The
immunogenicity outcome measures of interest include serum immunoglobulin G (IgG) and
immunoglobulin A (IgA) antibodies by Antibodies in Lymphocyte Supernatant (ALS) assay against
S. sonnei2a lipopolysaccharide (LPS), shedding profile of WRSS1, and vaccine-specific mucosal
IgA responses.
The proposed study builds upon successful preliminary observations with this vaccine in the
US, Israel and Thailand. While secondary objectives include studying the immunogenicity of
the WRSS1 vaccine, the primary goal of the current trial is to establish a clear safety
profile for the WRSS1 vaccine in adults and children 5-9 years old.The primary objective of
the study is to evaluate the safety and tolerability of the vaccine; the secondary objective
is to evaluate vaccine immunogenicity.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06283784 -
Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients
|
N/A | |
Recruiting |
NCT03851835 -
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
|
Phase 3 | |
Completed |
NCT04003181 -
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
|
N/A | |
Completed |
NCT03596827 -
The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
|
N/A | |
Recruiting |
NCT05372068 -
Cement flooRs AnD chiLd hEalth (CRADLE)
|
N/A | |
Completed |
NCT03972618 -
Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT05052489 -
Registry and Clinical Observation of Children With Diarrhoeal Disease
|
||
Completed |
NCT02428647 -
Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation
|
N/A | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT01968408 -
Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
|
Phase 3 | |
Completed |
NCT01739231 -
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Terminated |
NCT01472211 -
Water-based Zinc Intervention Trial in Zinc Deficient Children
|
Phase 0 | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Not yet recruiting |
NCT01382199 -
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
|
Phase 3 | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT00760851 -
Yogurt Study in Children 2-4 Years Old Attending Daycare
|
Phase 3 |